Top Clinical Trials companies in Belgium by EBITDA Margin

This ranking features the top 4 Clinical Trials companies in Belgium ranked by EBITDA Margin, averaging a EBITDA Margin of -1,271.00%, for February 07, 2025.

Belgium

Clinical Trials
EBITDA Margin
#
Name
EBITDA Margin
 Reported Date
Stock Price
Change
 Price (30 days) Country
1
GLPG.AS

Galapagos NV

1

GLPG.AS
18.45%
Dec. 31, 2023 USD 23.14 1.75%

Belgium
2
MDXH

MDxHealth SA

2

MDXH
-43.41%
Dec. 31, 2023 USD 1.91 0.00%

Belgium
3
NYXH

Nyxoah S.A.

3

NYXH
-967.80%
Dec. 31, 2023 USD 10.80 2.86%

Belgium
4
SEQUA.BR

Sequana Medical NV

4

SEQUA.BR
-4,091.26%
Dec. 31, 2023 USD 2.20 -1.56%

Belgium
Frequently Asked Questions
  • Which Clinical Trials company in Belgium has the highest EBITDA Margin ?

    The Clinical Trials company in Belgium with the highest EBITDA Margin is Galapagos NV (Amsterdam Stock Exchange: GLPG.AS) at 18.45%.

  • Which Clinical Trials company in Belgium has the lowest EBITDA Margin ?

    The Clinical Trials company in Belgium with the lowest EBITDA Margin is Sequana Medical NV (Brussels Stock Exchange: SEQUA.BR) at -4,091.26%.

SV Wall Street